Abstract
We measured to see high anti-IFNα antibody titers of two cases of chronic hepatitis C with genotype 2 who had non-end-of-treatment response (non-ETR) with pegylated interferon (PEG-IFN) plus ribavirin, so we treated by IFNβ. However HCV-RNA had good response to IFNβ, we couldn't get sustained virological response (SVR). Then we selected a combination therapy of IFNβ and ribavirin, and could get SVR. It is expected that the cases had anti-IFN antibody increase with an increase in retreatment and long-term administration of IFN. If HCV-RNA not decrease or decrease but reincrease during the combination therapy of PEG-IFN and ribavirin, you need to check the existence of anti-IFN antibody and measure that. In the case of positive anti-IFNα antibody, it is hoped IFNβ should be selected for IFN therapy of chronic hepatitis C.
